Paladin expands African roots with Litha partnership
This article was originally published in Scrip
Paladin Labs, the Canadian speciality pharmaceutical company, is expanding its reach into the sub-Saharan pharmaceuticals market by acquiring all the Pharmaplan shares it does not already hold and then merging the business with the pharma assets of Litha Healthcare, to become its largest shareholder with a 44.5% stake. The series of transactions will cost Paladin some Can$52 million.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.